VistaPharm Launches Unit Dose version of only approved Potassium Chloride Oral Solution product

Dec 14, 2015, 06:00 ET from VistaPharm

BIRMINGHAM, Ala., Dec. 14, 2015 /PRNewswire/ -- VistaPharm today announced that it has launched Potassium Chloride Solution, USP, 10% in Unit Dose. The product is supplied to the market in a 50 count case of 30mL unit dose cups.

Potassium Chloride is indicated for the treatment and prophylaxis of hypokalemia in patients for whom dietary management with potassium-rich foods or diuretic dose reduction are insufficient.

VistaPharm recently has entered a definitive agreement to be acquired by Vertice Pharma (www.verticepharma.com), a specialty pharmaceuticals company based in NJ for an undisclosed amount and it is subject to customary closing conditions.

About VistaPharm

Formed in 1998, VistaPharm is a Largo, Florida-based healthcare company that specializes in delivering generic pharmaceutical and OTC products for the hospital market, retail pharmacy and specialized clinical setting. For more information, please visit www.vistapharm.com

Forward-Looking Statement

Statements contained in this press release that refer to non-historical facts are forward-looking statements that reflect VistaPharm's current perspective of existing information as of the date of this release. It is important to note that VistaPharm's goals and expectations are not predictions of actual performance. Actual results may differ materially from VistaPharm's current expectations depending upon a number of factors, risks and uncertainties affecting VistaPharm's business. These factors include, among others, the impact of competitive products and pricing; the timing and success of product launches; difficulties or delays in manufacturing; the availability and pricing of third party sourced products and materials; successful compliance with FDA and other governmental regulations applicable to VistaPharm and its third party manufacturers' facilities, products and/or businesses; changes in the laws and regulations, including Medicare and Medicaid, affecting among other things, pricing and reimbursement of pharmaceutical products; and such other risks and uncertainties detailed in VistaPharm's periodic public filings with the Securities and Exchange Commission. Except as expressly required by law, VistaPharm disclaims any intent or obligation to update these forward-looking statements.

CONTACT:

VistaPharm
Suzette Allan
sallan@vistapharm.com
(205) 981-1387

SOURCE VistaPharm



RELATED LINKS

http://www.vistapharm.com